Advancing Off-the-Shelf CAR-NK Therapies for Safer, More Scalable Treatment of Cancer & Autoimmune diseases

• Explore how CAR-engineered NK cells enhance tumour targeting, persistence, and safety
• Discuss how these next-generation, allogeneic NK products improve manufacturability, cost efficiency, and clinical accessibility

New Data

Speakers:

Anna-Maria Georgoudaki

Senior Research Manager

Glycostem Therapeutics